



Less validation, less to store and less to waste.
More efficient, more convenient and more consistent.

Presaturated wipes: The most effective
and convenient method of cleanroom disinfection



Menu

- [Home](#)
- [Sectors](#)
- [Regions](#)
- [Events](#)
- [People](#)
- [Directory](#)

Search

5-Mar-2012

Shire receives EURORDIS Award

[Europe](#)



Shire has received the Company Award from the European Organisation for Rare Diseases (EURORDIS) for its work in the field of rare diseases.

The EURORDIS Company Award, presented at the first International Rare Disease Day Gala Dinner in Brussels, acknowledges the accomplishments of pioneering companies developing treatments for rare diseases. It is given to organisations that work closely with patient groups and strive to provide access to their products across the European Union.

EURORDIS is the largest European Patient Organisation in the field of rare diseases. It represents more than 500 rare disease organisations in 46 countries, covering more than 4,000 distinct rare diseases. Rare diseases affect around 30 million people across Europe.

Shire Human Genetic Therapies, a division of Shire plc, has more than 20 years' experience discovering, developing, manufacturing, and commercialising therapies for rare diseases. The company focuses its work on researching, developing and marketing therapies for Fabry disease, Hereditary Angioedema, Hunter syndrome, and Gaucher disease, and has built and invested in a pipeline of innovative products and solutions to treat them.

Sylvie Grégoire, president, Shire HGT, said: 'This award embodies the spirit of our organisation – every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' lives. Our partnerships with patient and advocacy organisations are vital in ensuring we

achieve this goal.’

Companies

- [Shire Pharmaceuticals](#)
- [EURORDIS](#)

ShareThis  

Subscriber Sign In

email:

password:

[Why subscribe?](#)

Related Articles

- [Galapagos receives €2.7m IWT grant for antibacterial research](#)
- [Galapagos discovers novel class of antibiotics](#)
- [Bellerophon Project awarded €5.5m by EU to develop S. aureus vaccine](#)
- [Medicago produces rotavirus VLP vaccine candidate](#)
- [Cobra Biologics and Novolytics develop bacteriophages against infection](#)
- [Drug resistance may make malaria parasites vulnerable to other substances](#)
- [GSK strengthens vaccines business with US\\$325m acquisition of Okairos](#)
- [MOD seeks innovative ways to develop antibiotics](#)
- [New European biotech Valneva SE is established](#)
- [Novo purchases Xellia Pharmaceuticals for US\\$700m](#)
- [Evotec and Harvard to develop new class of antibacterials](#)
- [Redx Pharma houses new venture at AZ R&D site in Alderley Park](#)

Related Press Releases

- [Public Health England and NanoViricides sign testing agreement](#)
- [Measles at highest level for 18 years in England and Wales](#)

Related Jobs

- [Lyonbiopole appoints General Manager](#)
- [Immunocore appoints Chief Business Officer](#)
- [Chimerix hires a Chief Development Officer](#)

- [About Manufacturing Chemist](#)
- [Contact Us](#)

- [About HPCi Media Limited](#)
- [Terms and Conditions](#)
- [Privacy](#)
- [^ Top](#)

